{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:21:53Z","timestamp":1793852513545,"version":"4.6.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann. Intensive Care"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treatment decisions on critically ill patients with circulatory shock lack consensus. In an international survey, we aimed to evaluate the indications, current practice, and therapeutic goals of inotrope therapy in the treatment of patients with circulatory shock.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From November 2016 to April 2017, an anonymous web-based survey on the use of cardiovascular drugs was accessible to members of the European Society of Intensive Care Medicine (ESICM). A total of 14 questions focused on the profile of respondents, the triggering factors, first-line choice, dosing, timing, targets, additional treatment strategy, and suggested effect of inotropes. In addition, a group of 42 international ESICM experts was asked to formulate recommendations for the use of inotropes based on 11 questions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 839 physicians from 82 countries responded. Dobutamine was the first-line inotrope in critically ill patients with acute heart failure for 84% of respondents. Two-thirds of respondents (66%) stated to use inotropes when there were persistent clinical signs of hypoperfusion or persistent hyperlactatemia despite a supposed adequate use of fluids and vasopressors, with (44%) or without (22%) the context of low left ventricular ejection fraction. Nearly half (44%) of respondents stated an adequate cardiac output as target for inotropic treatment. The experts agreed on 11 strong recommendations, all of which were based on excellent (&gt;\u200990%) or good (81\u201390%) agreement. Recommendations include the indications for inotropes (septic and cardiogenic shock), the choice of drugs (dobutamine, not dopamine), the triggers (low cardiac output and clinical signs of hypoperfusion) and targets (adequate cardiac output) and stopping criteria (adverse effects and clinical improvement).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Inotrope use in critically ill patients is quite heterogeneous as self-reported by individual caregivers. Eleven strong recommendations on the indications, choice, triggers and targets for the use of inotropes are given by international experts. Future studies should focus on consistent indications for inotrope use and implementation into a guideline for circulatory shock that encompasses individualized targets and outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13613-021-00806-8","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T07:18:20Z","timestamp":1611904700000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Current use of inotropes in circulatory shock"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-4190","authenticated-orcid":false,"given":"Thomas W. L.","family":"Scheeren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djillali","family":"Annane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Asfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Christiaan","family":"Boerma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Cecconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Cholley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cronhjort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"De Backer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaldo","family":"Dubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin W.","family":"D\u00fcnser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Duranteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludhmila A.","family":"Hajjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olfa","family":"Hamzaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanina","family":"Kanoore Edul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Koster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Landoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Mebazaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Monnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Payen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert M.","family":"Pearse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Pinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Radermacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Sakr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Saugel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervyn","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Squara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Vieillard-Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Vignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3891-8522","authenticated-orcid":false,"given":"Iwan C. C.","family":"van der Horst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon T.","family":"Vistisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Teboul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"issue":"3","key":"806_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/01.CCM.0000201896.45809.E3","volume":"34","author":"Y Sakr","year":"2006","unstructured":"Sakr Y, Reinhart K, Vincent JL, Sprung CL, Moreno R, Ranieri VM, et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med. 2006;34(3):589\u201397.","journal-title":"Crit Care Med"},{"issue":"12","key":"806_CR2","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s00134-014-3525-z","volume":"40","author":"M Cecconi","year":"2014","unstructured":"Cecconi M, De Backer D, Antonelli M, Beale R, Bakker J, Hofer C, et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med. 2014;40(12):1795\u2013815.","journal-title":"Intensive Care Med."},{"issue":"4","key":"806_CR3","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/01.ccx.0000135265.30310.77","volume":"10","author":"MH Weil","year":"2004","unstructured":"Weil MH. Personal commentary on the diagnosis and treatment of circulatory shock states. Curr Opin Crit Care. 2004;10(4):246\u20139.","journal-title":"Curr Opin Crit Care"},{"issue":"9","key":"806_CR4","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1056\/NEJMoa0907118","volume":"362","author":"D De Backer","year":"2010","unstructured":"De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779\u201389.","journal-title":"N Engl J Med"},{"issue":"18","key":"806_CR5","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMra1208943","volume":"369","author":"JL Vincent","year":"2013","unstructured":"Vincent JL, De Backer D. Circulatory shock. N Engl J Med. 2013;369(18):1726\u201334.","journal-title":"N Engl J Med"},{"issue":"1","key":"806_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13613-019-0498-7","volume":"9","author":"TWL Scheeren","year":"2019","unstructured":"Scheeren TWL, Bakker J, De Backer D, Annane D, Asfar P, Boerma EC, et al. Current use of vasopressors in septic shock. Ann Intensive Care. 2019;9(1):20.","journal-title":"Ann Intensive Care"},{"issue":"6","key":"806_CR7","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1097\/CCM.0b013e318174db05","volume":"36","author":"A Vieillard-Baron","year":"2008","unstructured":"Vieillard-Baron A, Caille V, Charron C, Belliard G, Page B, Jardin F. Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit Care Med. 2008;36(6):1701\u20136.","journal-title":"Crit Care Med"},{"issue":"3","key":"806_CR8","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","volume":"43","author":"A Rhodes","year":"2017","unstructured":"Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304\u201377.","journal-title":"Intensive Care Med"},{"issue":"2","key":"806_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00134-015-4041-5","volume":"42","author":"A Mebazaa","year":"2016","unstructured":"Mebazaa A, Tolppanen H, Mueller C, Lassus J, DiSomma S, Baksyte G, et al. Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance. Intensive Care Med. 2016;42(2):147\u201363.","journal-title":"Intensive Care Med"},{"issue":"27","key":"806_CR10","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129\u2013200.","journal-title":"Eur Heart J"},{"issue":"1","key":"806_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ahj.2006.09.005","volume":"153","author":"U Elkayam","year":"2007","unstructured":"Elkayam U, Tasissa G, Binanay C, Stevenson LW, Gheorghiade M, Warnica JW, et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J. 2007;153(1):98\u2013104.","journal-title":"Am Heart J"},{"issue":"5","key":"806_CR12","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/bja\/aev284","volume":"115","author":"A Belletti","year":"2015","unstructured":"Belletti A, Castro ML, Silvetti S, Greco T, Biondi-Zoccai G, Pasin L, et al. The Effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials. Br J Anaesth. 2015;115(5):656\u201375.","journal-title":"Br J Anaesth"},{"issue":"16","key":"806_CR13","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1161\/CIR.0000000000000525","volume":"136","author":"S van Diepen","year":"2017","unstructured":"van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, et al. Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association. Circulation. 2017;136(16):e232\u201368.","journal-title":"Circulation"},{"issue":"32","key":"806_CR14","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1093\/eurheartj\/ehz363","volume":"40","author":"H Thiele","year":"2019","unstructured":"Thiele H, Ohman EM, de Waha-Thiele S, Zeymer U, Desch S. Management of cardiogenic shock complicating myocardial infarction: an update 2019. Eur Heart J. 2019;40(32):2671\u201383.","journal-title":"Eur Heart J"},{"issue":"4","key":"806_CR15","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/MCC.0000000000000632","volume":"25","author":"B Levy","year":"2019","unstructured":"Levy B, Buzon J, Kimmoun A. Inotropes and vasopressors use in cardiogenic shock: when, which and how much? Curr Opin Crit Care. 2019;25(4):384\u201390.","journal-title":"Curr Opin Crit Care"},{"issue":"1","key":"806_CR16","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s13054-016-1387-1","volume":"20","author":"T Tarvasmaki","year":"2016","unstructured":"Tarvasmaki T, Lassus J, Varpula M, Sionis A, Sund R, Kober L, et al. Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality. Crit Care. 2016;20(1):208.","journal-title":"Crit Care"},{"issue":"2","key":"806_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00134-014-3604-1","volume":"41","author":"G Koster","year":"2015","unstructured":"Koster G, Wetterslev J, Gluud C, Zijlstra JG, Scheeren TW, van der Horst IC, et al. Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2015;41(2):203\u201321.","journal-title":"Intensive Care Med"},{"key":"806_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijcard.2017.10.077","volume":"251","author":"A Putzu","year":"2018","unstructured":"Putzu A, Clivio S, Belletti A, Cassina T. Perioperative levosimendan in cardiac surgery: A systematic review with meta-analysis and trial sequential analysis. Int J Cardiol. 2018;251:22\u201331.","journal-title":"Int J Cardiol"},{"issue":"21","key":"806_CR19","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa1616325","volume":"376","author":"G Landoni","year":"2017","unstructured":"Landoni G, Lomivorotov VV, Alvaro G, Lobreglio R, Pisano A, Guarracino F, et al. Levosimendan for Hemodynamic Support after Cardiac Surgery. N Engl J Med. 2017;376(21):2021\u201331.","journal-title":"N Engl J Med"},{"issue":"6","key":"806_CR20","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2017.9973","volume":"318","author":"B Cholley","year":"2017","unstructured":"Cholley B, Caruba T, Grosjean S, Amour J, Ouattara A, Villacorta J, et al. Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass: The LICORN Randomized Clinical Trial. JAMA. 2017;318(6):548\u201356.","journal-title":"JAMA"},{"issue":"21","key":"806_CR21","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1616218","volume":"376","author":"RH Mehta","year":"2017","unstructured":"Mehta RH, Leimberger JD, van Diepen S, Meza J, Wang A, Jankowich R, et al. Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. N Engl J Med. 2017;376(21):2032\u201342.","journal-title":"N Engl J Med"},{"issue":"17","key":"806_CR22","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1056\/NEJMoa1609409","volume":"375","author":"AC Gordon","year":"2016","unstructured":"Gordon AC, Perkins GD, Singer M, McAuley DF, Orme RM, Santhakumaran S, et al. Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis. N Engl J Med. 2016;375(17):1638\u201348.","journal-title":"N Engl J Med"},{"key":"806_CR23","first-page":"CD009669","volume":"1","author":"J Schumann","year":"2018","unstructured":"Schumann J, Henrich EC, Strobl H, Prondzinsky R, Weiche S, Thiele H, et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev. 2018;1:CD009669.","journal-title":"Cochrane Database Syst Rev."},{"issue":"Suppl 1","key":"806_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/cem.2014.77","volume":"17","author":"D Djogovic","year":"2015","unstructured":"Djogovic D, MacDonald S, Wensel A, Green R, Loubani O, Archambault P, et al. Vasopressor and Inotrope Use in Canadian Emergency Departments: Evidence Based Consensus Guidelines. CJEM. 2015;17(Suppl 1):1\u201316.","journal-title":"CJEM"},{"key":"806_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jcrc.2016.08.010","volume":"37","author":"A Belletti","year":"2017","unstructured":"Belletti A, Benedetto U, BiondiZoccai G, Leggieri C, Silvani P, Angelini GD, et al. The effect of vasoactive drugs on mortality in patients with severe sepsis and septic shock. A network meta-analysis of randomized trials. J Crit Care. 2017;37:91\u20138.","journal-title":"J Crit Care."},{"key":"806_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jclinane.2017.03.011","volume":"39","author":"S Bhattacharjee","year":"2017","unstructured":"Bhattacharjee S, Soni KD, Maitra S, Baidya DK. Levosimendan does not provide mortality benefit over dobutamine in adult patients with septic shock: A meta-analysis of randomized controlled trials. J Clin Anesth. 2017;39:67\u201372.","journal-title":"J Clin Anesth"},{"issue":"3","key":"806_CR27","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.2196\/jmir.6.3.e34","volume":"6","author":"G Eysenbach","year":"2004","unstructured":"Eysenbach G. Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES). J Med Internet Res. 2004;6(3):e34.","journal-title":"J Med Internet Res"},{"key":"806_CR28","unstructured":"Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, Lazaro P, et al. The RAND\/UCLA Appropriateness Method User's Manual. RAND Corporation. 2001."},{"key":"806_CR29","unstructured":"World Bank. World Bank country and lending groups. https:\/\/datahelpdeskworldbankorg\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups."},{"issue":"9","key":"806_CR30","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1007\/s00134-016-4449-6","volume":"42","author":"G Koster","year":"2016","unstructured":"Koster G, Bekema HJ, Wetterslev J, Gluud C, Keus F, van der Horst IC. Milrinone for cardiac dysfunction in critically ill adult patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Intensive Care Med. 2016;42(9):1322\u201335.","journal-title":"Intensive Care Med"},{"issue":"11","key":"806_CR31","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s00134-016-4482-5","volume":"42","author":"JL Vincent","year":"2016","unstructured":"Vincent JL. Improved survival in critically ill patients: are large RCTs more useful than personalized medicine? No Intensive Care Med. 2016;42(11):1778\u201380.","journal-title":"No Intensive Care Med"},{"issue":"4","key":"806_CR32","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s00134-016-4237-3","volume":"42","author":"F Lamontagne","year":"2016","unstructured":"Lamontagne F, Meade MO, Hebert PC, Asfar P, Lauzier F, Seely AJE, et al. Higher versus lower blood pressure targets for vasopressor therapy in shock: a multicentre pilot randomized controlled trial. Intensive Care Med. 2016;42(4):542\u201350.","journal-title":"Intensive Care Med"},{"issue":"4","key":"806_CR33","doi-asserted-by":"publisher","first-page":"R142","DOI":"10.1186\/cc9207","volume":"14","author":"O Hamzaoui","year":"2010","unstructured":"Hamzaoui O, Georger JF, Monnet X, Ksouri H, Maizel J, Richard C, et al. Early administration of norepinephrine increases cardiac preload and cardiac output in septic patients with life-threatening hypotension. Crit Care. 2010;14(4):R142.","journal-title":"Crit Care"},{"issue":"3","key":"806_CR34","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.bja.2017.11.065","volume":"120","author":"O Hamzaoui","year":"2018","unstructured":"Hamzaoui O, Jozwiak M, Geffriaud T, Sztrymf B, Prat D, Jacobs F, et al. Norepinephrine exerts an inotropic effect during the early phase of human septic shock. Br J Anaesth. 2018;120(3):517\u201324.","journal-title":"Br J Anaesth"},{"issue":"5","key":"806_CR35","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00134-018-5499-8","volume":"45","author":"G Hernandez","year":"2019","unstructured":"Hernandez G, Teboul JL, Bakker J. Norepinephrine in septic shock. Intensive Care Med. 2019;45(5):687\u20139.","journal-title":"Intensive Care Med"},{"issue":"6","key":"806_CR36","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00134-018-5242-5","volume":"44","author":"D Annane","year":"2018","unstructured":"Annane D, Ouanes-Besbes L, de Backer D, Du B, Gordon AC, Hernandez G, et al. A global perspective on vasoactive agents in shock. Intensive Care Med. 2018;44(6):833\u201346.","journal-title":"Intensive Care Med"},{"issue":"6","key":"806_CR37","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00134-018-5222-9","volume":"44","author":"V Leopold","year":"2018","unstructured":"Leopold V, Gayat E, Pirracchio R, Spinar J, Parenica J, Tarvasmaki T, et al. Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients. Intensive Care Med. 2018;44(6):847\u201356.","journal-title":"Intensive Care Med"},{"issue":"2","key":"806_CR38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacc.2018.04.051","volume":"72","author":"B Levy","year":"2018","unstructured":"Levy B, Clere-Jehl R, Legras A, Morichau-Beauchant T, Leone M, Frederique G, et al. Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction. J Am Coll Cardiol. 2018;72(2):173\u201382.","journal-title":"J Am Coll Cardiol"},{"key":"806_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jclinepi.2018.02.026","volume":"99","author":"I Neumann","year":"2018","unstructured":"Neumann I, Alonso-Coello P, Vandvik PO, Agoritsas T, Mas G, Akl EA, et al. Do clinicians want recommendations? A multicenter study comparing evidence summaries with and without GRADE recommendations. J Clin Epidemiol. 2018;99:33\u201340.","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"806_CR40","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1007\/s00134-010-1970-x","volume":"36","author":"EC Boerma","year":"2010","unstructured":"Boerma EC, Ince C. The role of vasoactive agents in the resuscitation of microvascular perfusion and tissue oxygenation in critically ill patients. Intensive Care Med. 2010;36(12):2004\u201318.","journal-title":"Intensive Care Med"},{"issue":"6","key":"806_CR41","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1007\/s00134-020-06025-2","volume":"46","author":"RF Stolk","year":"2020","unstructured":"Stolk RF, Kox M, Pickkers P. Noradrenaline drives immunosuppression in sepsis: clinical consequences. Intensive Care Med. 2020;46(6):1246\u20138.","journal-title":"Intensive Care Med"},{"issue":"4","key":"806_CR42","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/SHK.0b013e318289376b","volume":"39","author":"CA Schmittinger","year":"2013","unstructured":"Schmittinger CA, D\u00fcnser MW, Torgersen C, Luckner G, Lorenz I, Schmid S, et al. Histologic pathologies of the myocardium in septic shock: a prospective observational study. Shock. 2013;39(4):329\u201335.","journal-title":"Shock"},{"issue":"10","key":"806_CR43","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1007\/s00134-019-05731-w","volume":"45","author":"DB Antcliffe","year":"2019","unstructured":"Antcliffe DB, Santhakumaran S, Orme RML, Ward JK, Al-Beidh F, O\u2019Dea K, et al. Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial. Intensive Care Med. 2019;45(10):1392\u2013400.","journal-title":"Intensive Care Med"},{"issue":"16","key":"806_CR44","doi-asserted-by":"publisher","first-page":"e008455","DOI":"10.1161\/JAHA.117.008455","volume":"7","author":"L Lannemyr","year":"2018","unstructured":"Lannemyr L, Ricksten SE, Rundqvist B, Andersson B, Bartfay SE, Ljungman C, et al. Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment: A Randomized Double-Blind Controlled Trial. J American Heart Association. 2018;7(16):e008455.","journal-title":"J American Heart Association"},{"key":"806_CR45","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ahj.2018.07.009","volume":"204","author":"N Morici","year":"2018","unstructured":"Morici N, Oliva F, Ajello S, Stucchi M, Sacco A, Cipriani MG, et al. Management of cardiogenic shock in acute decompensated chronic heart failure: The ALTSHOCK phase II clinical trial. Am Heart J. 2018;204:196\u2013201.","journal-title":"Am Heart J"},{"issue":"9","key":"806_CR46","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/aas.13170","volume":"62","author":"M Fredholm","year":"2018","unstructured":"Fredholm M, Jorgensen K, Houltz E, Ricksten SE. Inotropic and lusitropic effects of levosimendan and milrinone assessed by strain echocardiography\u2014A randomised trial. Acta Anaesthesiol Scand. 2018;62(9):1246\u201354.","journal-title":"Acta Anaesthesiol Scand"}],"container-title":["Annals of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-021-00806-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13613-021-00806-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-021-00806-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:39:10Z","timestamp":1767767950000},"score":1,"resource":{"primary":{"URL":"https:\/\/annalsofintensivecare.springeropen.com\/articles\/10.1186\/s13613-021-00806-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["806"],"URL":"https:\/\/doi.org\/10.1186\/s13613-021-00806-8","relation":{},"ISSN":["2110-5820"],"issn-type":[{"value":"2110-5820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,29]]},"assertion":[{"value":"30 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A.M. received speaker\u2019s honoraria from Novartis, Orion, and Servier and fees as a member of the advisory board or steering committee from Adrenomed, Sanofi, Roche, Abbott, and 4TEEN4. The other authors have no competing interest to declare regarding this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"21"}}